Saturday 17 October 2026
Export GLUE’s income statement to Excel — free account
Monte Rosa Therapeutics, Inc.
GLUE Healthcare Biotechnology
Monte Rosa Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $123.7 million, up 63.5% from fiscal 2024. In the quarter to June 2026, revenue fell 61.3%, EPS fell 186.7% and free cash flow fell 34.1%, each against the same quarter a year earlier.
9.74
0.38
−3.75%
Follow GLUE
Monte Rosa Therapeutics, Inc. (GLUE) P/E ratio
Monte Rosa Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 66.6× (April 2025) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 23.2× | 84.84% |
| 6 more quarters | Free account |
Against its own ten years
Low 0.0×
High 66.6×
Ten-year median
0.0×
Current reading's percentile
72
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| KURA Kura Oncology, Inc. compare | n/m |
| VSTM Verastem, Inc. compare | n/m |
| GLUE Monte Rosa Therapeutics, Inc. | n/m |
| ALMS Alumis Inc. compare | n/m |
| ANRO Alto Neuroscience, Inc. compare | n/m |
| MLTX MoonLake Immunotherapeutics compare | n/m |
| AKTS Aktis Oncology, Inc. compare | n/m |
| JBIO Jade Biosciences, Inc. compare | n/m |
| RIGL Rigel Pharmaceuticals, Inc. compare | 2.6× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)